The heavily discounted convertible note with a low floor price and pre-delivery shares creates substantial potential dilution for existing shareholders. Monitor the stock price relative to the conversion price — if BDMD trades near or below the floor price, conversion could accelerate dilution. The investor's option to lend additional funds and participate in future financings suggests ongoing capital needs.
Price Chart
Executive Summary
Baird Medical Investment Holdings Ltd entered into a securities purchase agreement to issue an 8% senior secured original issue discount convertible note with a principal amount of $4,347,826, receiving net proceeds of $4,000,000 after a $347,826 original issue discount. The note is convertible into common stock at a fixed conversion price equal to 120% of the average three-day VWAP prior to closing, with a floor price of 20% of the minimum price under Nasdaq rules. The investor also has an option to lend an additional $3,680,000 within 180 days and up to $6 million more within 360 days, subject to conditions.
Key Facts
- Issued 8% senior secured convertible note with $4,347,826 principal amount, $4,000,000 net proceeds (8% original issue discount plus additional 2% discount of $86,956)
- Note matures 12 months from issuance date (September 2026)
- Conversion price is the lower of fixed price (120% of 3-day VWAP prior to closing) or 92% of lowest 7-day VWAP (85% if default)
- Floor price set at 20% of minimum price under Nasdaq rules
- 1,500,000 Pre-Delivery Shares issued to facilitate conversions
- Investor has right to participate in up to 25% of future financings for 18 months
- Company restricted from issuing variable-rate transactions and most equity for 180 days
- Lock-up agreements required from directors, officers, and 5% beneficial owners
- Cross-filing context: 20-F filed April 2026 showed 39% revenue decline in core microwave ablation devices and material weakness in internal controls
Financial Impact
Company receives $4,000,000 net proceeds from $4,347,826 note principal; potential additional $3,680,000 within 180 days and up to $6,000,000 more within 360 days subject to conditions
Risk Factors
- Significant dilution risk from conversion of the note at potentially deeply discounted prices
- Company's deteriorating fundamentals (39% revenue decline per 20-F) raise concerns about ability to service debt
- Material weakness in internal controls and recent auditor change indicate governance risks
- Potential for forced conversion or default if stock price falls below floor price
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-112324 |
| Document: tm2626149d1_ex10-2.htm | 0001104659-26-112324 |
| Document: tm2626149d1_ex10-3.htm | 0001104659-26-112324 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 6-K | $0.7440 | awaiting T+20 | — | $0.2820 (+62.10%) |
Sep 30, 2026 27d ago | 6-K | $0.7800 | awaiting T+20 | — | $0.2820 (−63.85%) |
Sep 3, 2026 7w ago | 6-K | $1.17 $0.7511 | ▼ −35.80% | ▼ −34.62% | $0.2820 (−75.90%) |
Sep 3, 2026 7w ago | Press Release | $1.17 $0.7511 | ▼ −35.80% | ▼ −34.62% | $0.2820 (−75.90%) |
Aug 18, 2026 10w ago | EFFECT | $1.09 $1.06 | ▲ +2.75% | ▲ +1.76% | $0.2820 (+74.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers